Ben Kozub is a highly accomplished commercial leader with over 25 years of experience spanning both large pharmaceutical companies and emerging biotech firms. His expertise in pre-commercial strategy, global product launches, and lifecycle management has been instrumental in driving growth for major therapeutic areas, including HIV prevention and rare liver diseases. With a passion for innovation and team leadership, Ben has developed and implemented transformative commercial strategies that have shaped product success in both established and new markets.
Currently serving as Senior Vice President and Head of Commercial at CymaBay Therapeutics, Ben is responsible for leading the U.S. commercial buildout and go-to-market strategy for the company’s first product launch in the rare liver disease space. Under his leadership, the team has laid a robust foundation across marketing, forecasting, competitive intelligence, and sales functions, ensuring a smooth pathway for CymaBay’s lead asset in primary biliary cholangitis. His work also extends globally, coordinating pre-commercial strategy in Europe and Asia and working closely with cross-functional teams to build commercial readiness.
Ben’s earlier career includes pivotal roles at BioMarin Pharmaceutical, where he prepared the market for the groundbreaking gene therapy ROCTAVIAN, aimed at transforming hemophilia A treatment. This role demanded not only innovative brand strategies and tactical planning but also careful navigation of regulatory landscapes to secure early product approvals. His approach emphasized data-driven decision-making and close collaboration with healthcare providers, enhancing the effectiveness of the go-to-market strategy and maximizing the product’s impact.
During his eight years at Gilead Sciences, Ben made a substantial impact on the U.S. HIV Prevention commercial organization. As Executive Director of PrEP, he spearheaded the launch and commercialization of TRUVADA and DESCOVY for PrEP, significantly improving HIV prevention standards. His visionary approach to direct-to-consumer campaigns and expansion of provider engagement helped the portfolio achieve over $2 billion in annual revenue. Ben’s work in this role highlighted his strategic acumen and adaptability within fast-evolving therapeutic markets.
Ben’s leadership style is grounded in his commitment to building and mentoring high-performing teams. Throughout his career, he has been known for hiring diverse, top-tier talent and fostering collaborative environments that empower individuals to exceed performance goals. His cross-functional leadership skills have been crucial in launching and managing multiple products and therapeutic portfolios across U.S. and global markets.
As a Point Foundation board member, Ben brings his expertise in mentorship and leadership development to the organization’s efforts in supporting LGBTQ+ students. This role aligns with his commitment to inclusivity and service, values that also inform his approach to corporate culture and team building. Ben’s dedication to both professional and community impact reflects a well-rounded leader focused on creating value in every aspect of his work.
Ben’s academic background includes a Juris Doctorate from Chicago-Kent College of Law, Illinois Institute of Technology, and a Bachelor of Arts in Journalism from Loyola University Maryland. His education laid the groundwork for his analytical and strategic thinking, essential skills that he has continuously honed through his professional journey.
In addition to his professional accomplishments, Ben is an avid runner and fitness enthusiast. He lives by the motto, “There is No Finish Line,” which mirrors his approach to both career and personal growth. Ben’s drive for longevity and resilience has fueled his successful career and inspired those around him to pursue continuous improvement.
Ben is now pursuing opportunities to serve on corporate boards where he can leverage his deep expertise in commercial strategy, global expansion, and patient-centered product launches to help emerging biotech and pharmaceutical companies achieve their full potential. With his unique blend of industry insight and hands-on experience, he is well-positioned to provide strategic guidance to companies navigating complex regulatory and commercial landscapes.
Character:
Ben Kozub embodies resilience and inclusivity, with a strong commitment to both professional excellence and community service. His dedication to continuous improvement and team empowerment reflects his steadfast character and leadership values.
Knowledge:
With extensive expertise in pharmaceutical commercialization and global market strategy, Ben has a deep understanding of the complexities and opportunities in emerging biotech and rare disease markets. His industry knowledge enables him to drive impactful product launches and lifecycle planning.
Strategic:
Ben’s forward-thinking approach to product development and commercialization leverages data-driven insights to maximize value and market position. His strategic mindset is evident in his ability to execute successful go-to-market plans and expand product portfolios globally.
Communication:
Known for his collaborative and inclusive leadership style, Ben excels in building high-performing, cross-functional teams. His clear communication fosters a shared vision, enabling his teams to consistently exceed goals and deliver impactful results.
